In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial

Heart Failure

Structural Abnormalities and Effects of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: The PARAGLIDE-HF Trial

Am Heart J

Kittipibul V, Cyr DD, Harrington J, Lala A, Fudim M, Ward JH, Sarwat S, Solomon SD, Hernandez AF, Zieroth S, Starling RC, Mentz RJ

doi: 10.1016/j.ahj.2025.05.004

Heart Failure

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperón G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD

doi: 10.1001/jamacardio.2025.0016

Heart Failure

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD

doi: 10.1001/jamacardio.2025.0860

Heart Failure

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry

Eur J Heart Fail

Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C, Čelutkienė J, Zdravkovic M, Bielecka-Dabrowa AM, Agostoni P, Xuereb RG, Neronova KV, Lelonek M, Cavusoglu Y, Gellen B, Abdelhamid M, Hammoudi N, Anker SD, Chioncel O, Filippatos G, Lainscak M, McDonagh TA, Mebazaa A, Piepoli M, Ruschitzka F, Seferović PM, Savarese G, Metra M, Rosano GMC, Maggioni AP, ESC EORP HF III National Leaders and Investigators

doi: 10.1002/ejhf.3445

Heart Failure

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Eur J Heart Fail

Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1002/ejhf.3661

Heart Failure

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

JAMA Cardiol

Abdel Jawad M, Spertus JA, Ikeaba U, Greene SJ, Fonarow GC, Chiswell K, Chan PS

doi: 10.1001/jamacardio.2024.4489

Heart Failure

Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1001/jamacardio.2024.4613

Heart Failure

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF

Eur J Heart Fail

Wang X, Vardeny O, Claggett B, Vaduganathan M, Hegde SM, Skali H, Pabon MA, Foà A, Chatur S, Kosztin A, O'Meara E, Rouleau J, Redfield M, Lam CSP, Zile M, Packer M, Shah AM, Cikes M, Gori M, Merkely B, Pfeffer MA, McMurray JJV, Solomon SD

doi: 10.1002/ejhf.3535

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Related content

Structural Abnormalities and Effects of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: The PARAGLIDE-HF Trial

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry